A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study of Anti CTLA-4 Antibody SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC
• Able and willing to provide a written informed consent
• ≥ 18 years old, both male and female
• Unresectable locally advanced or metastatic HCC confirmed by histopathologically/cytologically
• At least one measurable lesion based on RECIST v1.1 criteria
• Barcelona clinic liver cancer: Stage B or C
• No previous systemic antitumor therapy for HCC
• ECOG PS of 0-1
• Child-Pugh score of A or B7
• Expected survival period ≥ 12 weeks
⁃ Adequate organ function
⁃ Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception